Study design
TEAEs
This single-site, Phase III, randomized, open-label, masked-observer superiority trial includes four treatment arms: ivermectin 200μg/kg + albendazole 400mg (IA), moxidectin 8mg + albendazole 400mg (MoxA), ivermectin 200μg/kg + DEC 6mg/kg + albendazole 400mg (IDA), and moxidectin 8mg + DEC 6mg/kg + albendazole 400mg (MoxDA). Primary study endpoints are the proportion of participants having complete clearance of microfilaremia at 12 months (for the IA vs. MoxA comparison) and at 24 months (for IDA vs. MoxDA comparison). Secondary endpoints include the frequency and severity of TEAEs during the first 7 days after treatment. Participants were recruited from Agboville, Akoupé, Abengourou, and Bongounou Health Districts, in eastern Côte d’Ivoire (